scFv-TCR T Cell Therapy Development Service

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

scFv-TCR Fusion Construct

As a leading cell therapeutics provider, Creative Biolabs focuses on the genetic engineering of T cells for cancer immunotherapy. In order to improve the disadvantages of CAR-T cells in signal transduction, we synthesize a fusion construct (scFv-TCR) that consists of a tumor antigen-specific scFv fused to a TCR subunit (such as the CD3ε subunit). Upon introduction into T cells, the fusion construct is integrated into the TCR complex and leverages the signaling cascade of the complete TCR to kill cancer cells when tumor-specific antigens bind to scFvs. Given that scfv-TCR T cells leverage native TCR signaling instead of artificial signaling of the CAR, this strategy might improve the efficacy of existing CAR-T therapies for solid tumors.

Table.1 Comparison of CAR-T, TCR-T cells, and scFv-TCR T cells

	CAR-T cells	TCR-T cells	scFv-TCR T cells
Target antigen	Cell surface antigen	Peptide/MHC complex	Cell surface antigen
Extracellular binding	Tumor antigen-specific scFv	TCR	Tumor antigen-specific scFv
Intracellular signaling	Artificial signaling	TCR signaling	Entire TCR signaling
HLA restriction	HLA-Independent	HLA-dependent	HLA-Independent

Advantages

Attractive target options
Maximize antitumor efficacy
Improve safety
Longer persistence
Broad patient population

Design of Scfv-TCR Fusion Construct

In theory, there are several construct strategies since an anti-tumor-specific scFv can be fused to different TCR subunits, for example, TCRα, TCRβ, CD3γ, CD3δ, or CD3ε. The scFv fused to the CD3ε-/γ- subunits is the most common construct. The fusion construct is integrated into the TCR complex to form a functional TCR complex with novel target specificity, triggering a potent anti-tumor response. In addition, different scFv binders can be tethered to CD3ε-/γ- subunits, respectively, and upon integration into the TCR can generate dual targeting T cells.

Fig.1 The natural TCR complex and scfv-TCR fusion constructs.¹

One-stop scFv-TCR T Cell Development Services

Creative Biolabs is committed to supporting the cell therapy field of innovation by bringing together the best science, experience, and technologies. Drawing on our expertise in T-cell therapy development, we offer advanced customization options tailored to your specific needs. We provide a full range of TCR fusion construct-T cell development services, covering the design of scFv-TCR fusion construct, lentiviral production, T cell transduction, in vivo and in vitro functional assays. If you want to make a breakthrough in cancer immunotherapy, please feel free to contact us. Our scientist team is ready to understand your requirements and carry out your project. You will be updated with each stage of the project.

Reference

E Baeuerle, PA.; et al. Synthetic TRuC receptors engaging the complete T cell receptor for potent anti-tumor response. Nature communications. 2019, 10(1): 2087.

Key Updates

NEWSLETTER

The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders

LEARN MORE NEWSLETTER

NEW SOLUTION

CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.

LEARN MORE SOLUTION

NOVEL TECHNOLOGY

Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.

LEARN MORE NOVEL TECHNOLOGY

NEW SOLUTION

Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.

LEARN MORE SOLUTION